British multinational pharmaceutical company Hikma Pharmaceuticals has signed new exclusive licensing agreements with its long-standing partner, South Korea’s Celltrion, covering the Middle East and North Africa (MENA) region.

The agreements aim to expand access to cutting-edge and affordable biologics by introducing six biosimilar treatments across key therapeutic areas, including allergic diseases, ophthalmology, skeletal-related disorders, immune diseases, and oncology.

Under the deal, Hikma will hold exclusive commercialisation rights across all MENA markets, while Celltrion will be responsible for the development, manufacturing and supply of the treatments.

Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA, said, “We are proud to expand our partnership with Celltrion, reinforcing our shared commitment to improving access to high-quality biosimilar treatments. These treatments have the potential to significantly improve the quality of life for patients living with chronic, debilitating, or life-threatening conditions.”

“The addition of these biosimilars enhances Hikma’s ability to serve hospital channels with a comprehensive portfolio of injectables and biologics, reinforcing its ambition to become the top hospital player in the region,” he added.

The new agreements reinforce Hikma’s position as a leading provider of biosimilars in the MENA region.